$26.16
1.47% today
Nasdaq, Dec 04, 10:00 pm CET
ISIN
US81734D1046
Symbol
SEPN

Septerna Stock price

$26.16
+6.70 34.43% 1M
+16.19 162.39% 6M
+3.26 14.24% YTD
+0.10 0.38% 1Y
+8.16 45.33% 3Y
+8.16 45.33% 5Y
+8.16 45.33% 10Y
+8.16 45.33% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
-0.39 1.47%
ISIN
US81734D1046
Symbol
SEPN
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | 743.7
P/S
53.9 | 15.6
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
92.0%
Return on Equity
-17.1%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$22.1m | $76.3m
EBITDA
$-87.9m | $-65.3m
EBIT
$-89.5m | $-13.2m
Net Income
$-58.8m | -
Free Cash Flow
$103.2m
Growth (TTM | estimate)
Revenue
2,150.0% | 6,960.7%
EBITDA
-341.0% | 17.8%
EBIT
-310.7% | 83.6%
Net Income
-196.3% | -
Free Cash Flow
215.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-398.7% | -85.6%
EBIT
-406.0%
Net
-266.8% | -
Free Cash Flow
467.9%
More
EPS
$-1.3
FCF per Share
-
Short interest
7.4%
Employees
-
Rev per Employee
-
Show more

Is Septerna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Septerna Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Septerna forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Septerna forecast:

Buy
82%
Hold
18%

Financial data from Septerna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
22 22
2,150% 2,150%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
89% 89%
120%
- Research and Development Expense 85 85
51% 51%
386%
-88 -88
341% 341%
-399%
- Depreciation and Amortization 1.59 1.59
15% 15%
7%
EBIT (Operating Income) EBIT -89 -89
311% 311%
-406%
Net Profit -59 -59
196% 196%
-267%

In millions USD.

Don't miss a Thing! We will send you all news about Septerna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Septerna Stock News

Neutral
GlobeNewsWire
9 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 a.m. ET in Coral Gables, Florida.
Positive
Seeking Alpha
10 days ago
Septerna, Inc. delivered a strong 3Q25, driven by partnership revenue from its transformative collaboration with Novo Nordisk. SEPN's Novo partnership brings $195M upfront, a potential $2.2B in milestones, and full R&D funding, reducing capital burden and boosting strategic position. The incretin-pathway GPCR program is closest to early milestones, with further upside tied to successful target ...
Neutral
GlobeNewsWire
24 days ago
SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expected to Support Operations at Least into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new e...
More Septerna News

Company Profile

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeffrey Finer
Website septerna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today